8-K: BioAffinity Reports Record CyPath Lung Sales, Strategic Shift

BioAffinity Technologies announced record 2025 revenue and unit sales for its flagship lung cancer diagnostic, CyPath Lung, alongside a strategic streamlining of its laboratory business.

Summary

• Record CyPath Lung revenue and unit sales were achieved in 2025.
• Revenue from CyPath Lung increased 87% over 2024, with the number of tests performed rising 99% year-over-year.
• Orders for CyPath Lung by physicians and clinics rose 67% year-over-year.
• Total consolidated revenue decreased 34% to $6.2 million in 2025, down from $9.4 million in 2024, due to the discontinuation of unprofitable pathology services.
• Operating expenses decreased 9% to $16.7 million in 2025, compared to $18.3 million in 2024.
• Net loss for the year ended December 31, 2025, was $14.9 million, an increase from $9.0 million in 2024.
• Cash and cash equivalents as of December 31, 2025, were $6.5 million, significantly up from $1.1 million at the end of 2024.
• Approximately $16.9 million in gross proceeds was raised during 2025 from equity transactions to fund clinical development, commercialization, and operational expansion.
• Research and development continued on diagnostic tests for chronic obstructive pulmonary disease (COPD) and asthma, with patient studies expected to begin in 2026.
• The intellectual property portfolio was strengthened in 2025 with multiple patent allowances and acceptances in the U.S., Canada, China, and Australia.
• The first patient was enrolled in a longitudinal study evaluating CyPath Lung in March 2026, with plans to enroll up to 2,000 patients across 17 medical centers.
• A collaboration with Brooke Army Medical Center (BAMC) was announced in February 2026 to evaluate CyPath Lung on sputum samples obtained via tracheal and bronchial suctioning.
• Ten patient case studies were released in 2025, and two new real-world clinical cases in February 2026, validating CyPath Lung's efficacy.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting successful strategic execution in focusing on the core CyPath Lung product, which shows strong growth and market adoption, despite a temporary dip in consolidated revenue due to divesting unprofitable services and an increased net loss.

Positives

• CyPath Lung revenue increased 87% year-over-year, reflecting growing clinical utilization.
• The number of CyPath Lung tests performed rose 99% year-over-year.
• The physician network expanded, with orders for CyPath Lung increasing 67% over 2024.
• Operating expenses decreased 9% due to strategic streamlining and reallocation of resources.
• Cash and cash equivalents significantly increased to $6.5 million as of December 31, 2025, from $1.1 million in 2024.
• Successfully raised approximately $16.9 million in gross proceeds from equity transactions in 2025.
• Strengthened intellectual property portfolio with multiple patent allowances and acceptances globally.
• Key leadership appointments, including a Chief Medical Officer and two Board members, bring extensive industry experience.
• Initiated a large longitudinal trial for CyPath Lung and a collaboration with Brooke Army Medical Center to expand sample collection options.
• Positive real-world case studies continue to validate CyPath Lung's ability to detect early-stage lung cancer and guide physician decision-making.
• Progress in the innovation pipeline with expected patient studies for COPD and asthma diagnostics in 2026.

Negatives

• Total consolidated revenue decreased 34% to $6.2 million in 2025, down from $9.4 million in 2024, due to the discontinuation of unprofitable pathology services.
• Net loss increased to $14.9 million in 2025 from $9.0 million in 2024.
• The increase in net loss was primarily attributable to changes in the fair value of warrants, expanded sales activities, and increased clinical development.

Risks

• Ability to successfully commercialize and achieve market acceptance of CyPath Lung.
• Ability to raise additional capital to fund operations.
• History of losses and ability to achieve profitability.
• Reliance on CyPath Lung as its primary revenue-generating product.
• Changes in the regulatory landscape for laboratory developed tests, including potential FDA oversight.
• Ability to obtain and maintain adequate reimbursement from third-party payors.
• Outcome of clinical trials and studies.
• Ability to attract and retain qualified personnel.
• Competition from existing and new diagnostic techniques.
• Ability to protect intellectual property.
• Ability to maintain Nasdaq listing.
• General economic, political, and market conditions.

Future Outlook

BioAffinity expects CyPath Lung unit sales to increase by greater than 100% over 2025, with a corresponding increase in revenues. The company plans to expand its market geographically and by the number of physicians and medical facilities. The market opportunity for indeterminate pulmonary nodules is projected to exceed $4.7 billion by 2030, and for post-treatment surveillance for lung cancer survivors, an estimated $870 million over the next decade. Patient studies for COPD and asthma diagnostics are expected to begin in 2026.

Management Comments

• "2025 was a transformational year for bioAffinity Technologies. We took deliberate actions to streamline operations at PPLS and align our resources behind the national expansion of CyPath Lung." Maria Zannes, President and Chief Executive Officer.
• "While these actions contributed to a decrease in consolidated revenue, we believe that the Company is now better positioned to leverage revenue generated from the profitable testing services performed in our lab." Maria Zannes, President and Chief Executive Officer.
• "Importantly, revenue for our core value driver, CyPath Lung, increased 87% year over year, reflecting continued physician adoption and growing clinical utilization." Maria Zannes, President and Chief Executive Officer.
• "The work we accomplished in 2025 was intentional and strategic. We strengthened our capital base, removed unprofitable legacy services from PPLS services and concentrated on high-value diagnostics." Maria Zannes, President and Chief Executive Officer.
• "The launch of our longitudinal trial and our ongoing integration into the military healthcare system are both significant milestones that support our strategy of establishing CyPath Lung as a standard of care for indeterminate pulmonary nodules and a tool for surveillance after cancer treatment." Maria Zannes, President and Chief Executive Officer.
• "Every day, we hear from practitioners who confirm the need for noninvasive, accurate lung cancer diagnostics, particularly when imaging and risk models are inconclusive or turn out to be wrong. CyPath Lung remains our first priority. It is a gamechanger that provides clinical confidence for physicians and better outcomes for patients." Maria Zannes, President and Chief Executive Officer.
• "We believe our focus on improving care for patients at risk for lung cancer and other pulmonary diseases will create long-term value for our shareholders." Maria Zannes, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that BioAffinity Technologies' strategic pivot to focus solely on its high-value CyPath Lung diagnostic aligns with a broader industry trend towards specialized, high-margin diagnostic solutions, particularly in oncology. The projected growth in indeterminate pulmonary nodules and lung cancer survivorship highlights a significant and expanding market for noninvasive detection and surveillance tools, positioning CyPath Lung favorably against traditional, more invasive methods. The expansion into COPD and asthma diagnostics also leverages existing platform technology, indicating a strategic move to diversify and capture additional market share in related respiratory diseases, a segment with substantial global impact.

Comparison to Industry Standards

• CyPath Lung's clinical study results demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules (less than 20 millimeters). This performance is competitive with or superior to other non-invasive lung cancer detection methods, which often struggle with high false-positive rates or lower sensitivity in early stages.
• The projected market opportunity for indeterminate pulmonary nodules exceeding $4.7 billion by 2030, driven by increased lung cancer screening adoption and improved adherence to guidelines, suggests a significant unmet need that CyPath Lung aims to address. This market size is comparable to other high-growth diagnostic segments in oncology.
• The estimated $870 million market opportunity for post-treatment surveillance for lung cancer survivors over the next decade indicates a substantial niche, as current surveillance often involves repeated imaging and invasive procedures, which CyPath Lung could potentially reduce.
• The company's expansion into COPD and asthma diagnostics, targeting specific receptors for therapies like dupilumab and benralizumab, positions it in a competitive landscape with companies developing personalized medicine approaches for chronic respiratory diseases, such as AstraZeneca (developing therapies for severe asthma) and Regeneron/Sanofi (marketing Dupixent for asthma and COPD).

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through focused commercialization of CyPath Lung and pipeline development; dilution from 2025 equity raises; increased net loss in the short term.
• Patients: Improved access to noninvasive, accurate early-stage lung cancer diagnostics (CyPath Lung); potential for personalized treatment guidance for asthma and COPD.
• Physicians/Clinics: Growing awareness and adoption of CyPath Lung as a valuable diagnostic tool, supported by peer-to-peer marketing and case studies.
• Employees: Strategic streamlining of laboratory business may have impacted some roles, but focus on CyPath Lung commercialization could lead to growth in other areas.
• Regulatory Authorities: Potential for increased FDA oversight on Laboratory Developed Tests (LDTs) is a noted risk.

Next Steps

• Expand sales force into new markets in 2026.
• Continue to expand the market for CyPath Lung geographically and by the number of physicians and medical facilities.
• Continue the longitudinal study evaluating CyPath Lung, enrolling up to 2,000 patients.
• Continue the collaboration with Brooke Army Medical Center (BAMC) to evaluate CyPath Lung on sputum samples obtained via tracheal and bronchial suctioning.
• Begin patient studies for diagnostic tests for chronic obstructive pulmonary disease (COPD) and asthma in 2026.
• File the Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The company demonstrated strong growth in its flagship CyPath Lung product, with significant increases in revenue and unit sales, and successfully raised substantial capital. The strategic decision to divest unprofitable services is a positive long-term move. However, the company continues to report a net loss, and its future success hinges on the successful commercialization of CyPath Lung, navigating regulatory changes, and securing further reimbursement. Given the strong product performance but ongoing financial challenges and execution risks, a 'hold' recommendation is appropriate for investors to monitor continued progress in market adoption and profitability.

Keywords

lung cancer diagnostic, CyPath Lung, biotechnology, noninvasive test, early-stage cancer detection, flow cytometry, COPD, asthma, medical devices, clinical trials, intellectual property, Nasdaq, healthcare, diagnostics